Analysis of whether isatuximab (Xalcoyi) requires long-term medication and its safety

Isatuximab (Isatuximab) is an antiCD38 monoclonal antibody, mainly used for the treatment of multiple myeloma. Its mechanism of action is to induce tumor cell apoptosis by targeting the CD38 receptor, while activating immune effector cells in the body to enhance the clearance of myeloma cells. Because its action is an immune-targeting mechanism, it usually needs to be used in combination with chemotherapy or other targeted drugs to obtain the best therapeutic effect.

In terms of medication cycle, isatuximab treatment is mostly a long-term maintenance regimen. Clinical studies have shown that patients with multiple myeloma who receive isatuximab in combination with chemotherapy or other drugs require continued administration to maintain efficacy and prolong progression-free survival. Treatment frequency and dosage are usually adjusted based on the patient's tolerance and blood parameters. The initial administration may be once a week, and the maintenance period can be extended to once every two weeks or every four weeks to balance efficacy and safety.

Regarding drug safety, isatuximab is generally well tolerated, but infusion reactions, hematological abnormalities, and infection risks still need to be paid attention to. Symptoms such as fever, chills, headache or hypotension may occur during the initial infusion, which can generally be relieved by slowing down the infusion rate or pre-administering anti-allergic drugs. Long-term medication requires regular monitoring of blood routine, liver and kidney function, and immune indicators in order to promptly detect adverse reactions and adjust treatment plans.

In general, isatuximab (Isatuximab) usually requires long-term medication to maintain myeloma control, but during use, doctors’ instructions should be strictly followed, with regular follow-up and monitoring of various indicators. Through individualized dose adjustment and combination treatment strategies, safety risks can be minimized while ensuring efficacy, and patients' quality of life and treatment compliance can be improved.

Keyword tags: isatuximab, multiple myeloma,CD38targeting, long-term maintenance, infusion reaction

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma